Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites?3. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition燣abel. It is currently available under the brand name Removab.

货号（Catalog No.）icon

CSD00133

通用名INNicon

Catumaxomab

纯度(Purity)icon

>95%

浓度( Concentration)icon

1mg/ml

Formulationicon

PBS buffer pH7.5

Sourceicon

CHO cells

内毒素(Endotoxin level)icon

Please contact with the lab for this information.

生物活性icon

产品描述(Description)

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites 3. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition Label. It is currently available under the brand name Removab.

别名(Alternative names)

Musmus G2a kappa,anti-EPCAM (Ho-3/TP-A-01)/Rat sp.G2b lambda,anti-CD3E (26/II/6-1.2),TPBs01

靶点;物种(Specificity target name;species)

CD3E/EpCAM[Homo sapiens]

种类(Species)

Mus musculus,Rattus sp,Hybrid

受体鉴定(Receptor identification)

IgG2a-kappa/G2b-lambda

化学信息icon

分子量(MV)

150511.00 Da

CAS

509077-98-9

存储条件(Storage)

store at -80°C

Note
For research use only .